https://www.selleckchem.com/products/ms4078.html
Furthermore, the blood ammonia levels significantly decreased at the time of the switching to rifaximin and at three and six months later (p=0.043 and p=0.011, respectively). Conclusion Switching to rifaximin in hepatic cirrhosis patients receiving kanamycin sulfate to treat hepatic encephalopathy and hyperammonemia showed effects that were equivalent to or greater than the original therapy, thereby demonstrating the clinical efficacy.Fabry disease (FD) is an X-linked lysosomal storage disorder resulting from a lack of alpha-galactosidas
Like
Comment
Share
